Skip to content

Study · Randomized controlled trial · n = 757 · 2012

8 results

Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.

Weiss JP, Zinner NR, Klein BM, Nørgaard JP

Neurourology and urodynamics22 Mar 2012Cited by 80 (Europe PMC)

PMID22447415 (opens in a new tab)DOI10.1002/nau.22243 (opens in a new tab)PepBankPUB-22447415
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, increasing desmopressin doses were associated with fewer nocturnal voids.

    In plain wordsIn adults with nocturia, higher desmopressin doses were linked to fewer nightly urinations than lower doses.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturnal voids
    Study

    n = 757

    Comparator
    Placebo and other desmopressin doses (10, 25, 50, 100 µg)
    Outcome group
    Nocturia · Kidney and urinary
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and voided volume, greater proportions of subjects with >33% reduction in nocturnal voids, and increased duration of first sleep period.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, increasing desmopressin doses were associated with lower voided volume.

    In plain wordsIn adults with nocturia, higher desmopressin doses were linked to lower urine volumes than lower doses.

    Peptide
    Desmopressin
    Outcome
    DecreaseVoided volume
    Study

    n = 757

    Comparator
    Placebo and other desmopressin doses (10, 25, 50, 100 µg)
    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and voided volume, greater proportions of subjects with >33% reduction in nocturnal voids, and increased duration of first sleep period.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, increasing desmopressin doses were associated with more subjects achieving greater than 33% reduction in nocturnal voids.

    In plain wordsIn adults with nocturia, higher desmopressin doses were linked to more responses above 33% than lower doses.

    Peptide
    Desmopressin
    Outcome
    IncreaseMore than 33% nocturnal-void reduction
    Study

    n = 757

    Comparator
    Placebo and other desmopressin doses (10, 25, 50, 100 µg)
    Outcome group
    Nocturia · Kidney and urinary
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and voided volume, greater proportions of subjects with >33% reduction in nocturnal voids, and increased duration of first sleep period.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, increasing desmopressin doses were associated with longer first sleep periods.

    In plain wordsIn adults with nocturia, higher desmopressin doses were linked to longer first sleep periods than lower doses.

    Peptide
    Desmopressin
    Outcome
    IncreaseFirst sleep period duration
    Study

    n = 757

    Comparator
    Placebo and other desmopressin doses (10, 25, 50, 100 µg)
    Outcome group
    Sleep · Sleep
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Increasing doses of desmopressin were associated with decreasing numbers of nocturnal voids and voided volume, greater proportions of subjects with >33% reduction in nocturnal voids, and increased duration of first sleep period.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  5. 05HumanNon-randomized trialSafety outcome

    In adults with nocturia, desmopressin was generally well tolerated.

    In plain wordsIn adults with nocturia, desmopressin was generally well tolerated.

    Peptide
    Desmopressin
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Desmopressin was generally well tolerated.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  6. 06HumanNon-randomized trialSafety outcome

    In women with nocturia taking desmopressin above 25 µg, six had serum sodium below 125 mmol/L.

    In plain wordsIn women with nocturia taking desmopressin above 25 µg, six had sodium below 125 mmol/L.

    Peptide
    Desmopressin
    Outcome
    Not applicableSerum sodium below 125 mmol/L in women
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    >25 µg · oral · 4 weeksAs given in this study (human).

    Measurements

    Women with serum sodium <125 mmol/L
    6 women
    desmopressin >25 µg

    Source sentences

    Summary
    Reductions in serum sodium to 25 µg desmopressin) and two men (aged 67 and 82) taking 100 µg, support lower and gender-specific dosing to reduce the small but clinically significant risk of hyponatraemia.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  7. 07HumanNon-randomized trialSafety outcome

    In men with nocturia taking desmopressin 100 µg, two men aged 67 and 82 had serum sodium below 125 mmol/L.

    In plain wordsIn men with nocturia taking desmopressin 100 µg, two had sodium below 125 mmol/L.

    Peptide
    Desmopressin
    Outcome
    Not applicableSerum sodium below 125 mmol/L in men
    Study

    n: not reported in source

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    100 µg · oral · 4 weeksAs given in this study (human).

    Measurements

    Men with serum sodium <125 mmol/L
    2 men
    desmopressin 100 µg

    Source sentences

    Summary
    Reductions in serum sodium to 25 µg desmopressin) and two men (aged 67 and 82) taking 100 µg, support lower and gender-specific dosing to reduce the small but clinically significant risk of hyponatraemia.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.
  8. 08HumanObservational studyEfficacy outcome

    In adults with nocturia, post hoc analyses suggested a lower minimum effective desmopressin dose in women than men.

    In plain wordsIn adults with nocturia, post hoc analyses suggested a lower minimum effective desmopressin dose in women than men.

    Peptide
    Desmopressin
    Outcome
    DecreaseMinimum effective dose by sex
    Study

    n: not reported in source

    Comparator
    Men
    Outcome group
    Nocturia · Kidney and urinary
    Studied dose
    10, 25, 50, or 100 µg · oral · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Post hoc analyses by gender suggested a lower minimum effective dose for women.
    1 context sentence
    Summary · context
    This was a 4-week, randomized, double-blind study comparing 10, 25, 50, or 100 µg desmopressin versus placebo in adults with defined nocturia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00477490

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Ferring Pharmaceuticalsn = 799May 2007 to Feb 2008

Nocturia

Trial pageClinicalTrials.govUpdated 2 Nov 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.